Revista de Chimie https://revistadechimie.ro https://doi.org/10.37358/Rev. Chim.1949 Rev. Chim., 71 (3), 2020, 325-334 325 https://doi.org/10.37358/RC.20.3.8005 Fluconazole-Beta-Cyclodextrin Inclusion Complexes. Preparation and Characterization in Solid State ANDRADA IFTODE 1# , ROXANA RACOVICEANU 1# , RAZVAN SUSAN 2# , DANIELA MARTI 3# , IULIA PINZARU 1* , RADU LAZAU 4* , MONICA SUSAN 2 , ALEXANDRA GHEORGHISOR 1 , CODRUTA SOICA 1 , CRISTINA TRANDAFIRESCU 1 1 ”Victor Babes” University of Medicine and Pharmacy, Faculty of Pharmacy, 2 nd Eftimie Murgu Sq., 300041, Timisoara, Romania 2 ”Victor Babes” University of Medicine and Pharmacy, Faculty of Medicine, 2 nd Eftimie Murgu Sq., 300041, Timisoara, Romania 3 Western University Vasile Goldis Arad, 94 Revolutiei Blvd., 310025, Arad, Romania 4 Politehnica University Timisoara, 2 nd Victoriei Sq., 300006, Timisoara, Romania Abstract: Fluconazole is a bistriazole derivative with antifungal activity. The major weak points of fluconazole are the development of antifungal resistance and low water solubility, which impairs its administration. Binary systems between fluconazole and beta-cyclodextrin were prepared with the aim of obtaining a new delivery system that will overcome the limitations of fluconazole administration. Using two feasible laboratory methods, inclusion complexes between fluconazole and beta- cyclodextrin were obtained. Thermal and spectroscopic analyses were used to characterize the inclusion complexes. Keywords: fluconazole, beta-cyclodextrin, inclusion complex 1. Introduction Fluconazole (2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol, IUPAC), is a bis- triazole derivative with antifungal activity (Figure 1) [1]. Figure 1. Structural formula of fluconazole Fluconazole (FLU) is a fungistatic agent being predominantly active against Candida species, Cryptooccus neoformans, Histoplasma, Blastomyces and Coccidioides species. Fluconazole is mainly indicated for the treatment and prophylaxis of disseminated and deep organ candidiasis in both normal and immune compromised patients and is considered the agent of choice for the treatment of cryptococcal meningitis and for prophylaxis of cryptococcosis in AIDS patients. Fluconazole has shown only weak activity against Aspergillus species [2-4]. *email: iuliapinzaru@umft.ro; radu.lazau@upt.ro # Authors with equal contribution